|
 Results of a Phase III study involving 185 patients with
HER2-negative metastatic breast cancer found those treated with both
drugs saw an almost threefold improvement in how long they lived
without their disease getting worse compared with those taking
Avastin alone.
A second late-stage trial with 494 patients who continued treatment
with Avastin and standard chemotherapy after their disease had
progressed showed patients lived significantly longer without the
disease getting worse compared with those treated only with
chemotherapy.
Roche said it would present full results of both studies at the
European Society of Medical Oncology congress on Sept. 28.
(Reporting by Maria Sheahan; Editing by Pravin Char)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
